<table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl2" position="float"><object-id pub-id-type="doi">10.7554/eLife.02565.008</object-id><label>Table 2.</label><caption><p>Model parameters and symbolic representations</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.02565.008">http://dx.doi.org/10.7554/eLife.02565.008</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameter</th><th>Representation</th><th>Baseline value (see <xref ref-type="table" rid="tbl1">Table 1</xref>)</th></tr></thead><tbody><tr><td>Transmission rate (transmission events per highly  infectious person-year)</td><td><italic>&#946;</italic></td><td>Calibrated to TB incidence</td></tr><tr><td>Proportional reduction in per-case transmission rate</td><td/><td/></tr><tr><td>&#8195;Drug-susceptible TB</td><td><italic>&#966;</italic><sub>0</sub></td><td>1.0</td></tr><tr><td>&#8195;Isoniazid-monoresistant TB</td><td><italic>&#966;</italic><sub>1</sub></td><td>25%<xref ref-type="table-fn" rid="tblfn3">*</xref> of <italic>&#966;</italic><sub><italic>2</italic></sub></td></tr><tr><td>&#8195;MDR-TB</td><td><italic>&#966;</italic><sub>2</sub></td><td>Calibrated</td></tr><tr><td>HIV incidence rate, per year</td><td><italic>&#952;</italic></td><td>Calibrated to HIV prevalence</td></tr><tr><td>Relative transmission rate from smear-negative/less  infectious TB</td><td><italic>&#950;</italic></td><td>0.22</td></tr><tr><td>Proportion of pulmonary TB that is smear-positive/highly  infectious</td><td/><td/></tr><tr><td>&#8195;HIV-negative</td><td><italic>&#968;</italic><sub>0</sub></td><td>0.63</td></tr><tr><td>&#8195;HIV-infected</td><td><italic>&#968;</italic><sub>1</sub></td><td>0.50</td></tr><tr><td>Endogenous reactivation rate, per year</td><td/><td/></tr><tr><td>&#8195;HIV-negative</td><td><italic>&#949;</italic><sub>0</sub></td><td>0.005</td></tr><tr><td>&#8195;HIV-infected</td><td><italic>&#949;</italic><sub>1</sub></td><td>0.05</td></tr><tr><td>Proportion of recent infections resulting in rapid  progression</td><td/><td/></tr><tr><td>&#8195;HIV-negative</td><td><italic>&#960;</italic><sub>0</sub></td><td>0.14</td></tr><tr><td>&#8195;HIV-infected</td><td><italic>&#960;</italic><sub>1</sub></td><td>0.47</td></tr><tr><td>Reduction in TB rapid progression probability due to  latent TB infection</td><td/><td/></tr><tr><td>&#8195;HIV-negative</td><td><italic>&#953;</italic></td><td>0.79</td></tr><tr><td>&#8195;HIV-infected</td><td>Not included</td><td>0</td></tr><tr><td>Baseline mortality rate, per year</td><td><italic>&#956;</italic><sub><italic>bl</italic></sub></td><td>1/55 = 0.018</td></tr><tr><td>Additional HIV-related mortality rate, per year</td><td><italic>&#956;</italic><sub><italic>h</italic></sub></td><td>0.05</td></tr><tr><td>Additional untreated TB-related mortality rate, per year</td><td/><td/></tr><tr><td>&#8195;HIV-negative, smear-positive/highly infectious</td><td><italic>&#956;</italic><sub><italic>t</italic>1</sub></td><td>0.23</td></tr><tr><td>&#8195;HIV-negative, smear-negative/less infectious</td><td><italic>&#956;</italic><sub><italic>t</italic>0</sub></td><td>0.07</td></tr><tr><td>&#8195;HIV-infected</td><td><italic>&#956;</italic><sub><italic>th</italic></sub></td><td>1.0</td></tr><tr><td>Rate of spontaneous TB resolution, per year</td><td/><td/></tr><tr><td>&#8195;Smear-positive/highly infectious</td><td><italic>&#957;</italic><sub>1</sub></td><td>0.1</td></tr><tr><td>&#8195;Smear-negative/less infectious</td><td><italic>&#957;</italic><sub>0</sub></td><td>0.27</td></tr><tr><td>&#8195;HIV-infected</td><td>Not included</td><td>0</td></tr><tr><td>Rate of starting diagnosis-seeking in active TB, per year</td><td/><td/></tr><tr><td>&#8195;HIV-negative</td><td><italic>&#948;</italic><sub><italic>e</italic>0</sub></td><td>1.33 (9 months)</td></tr><tr><td>&#8195;HIV-infected</td><td><italic>&#948;</italic><sub><italic>e</italic>1</sub></td><td>12 (1/month)</td></tr><tr><td>Rate of progression: ineffective therapy to repeat  therapy (failure) or active TB (relapse), per year</td><td><italic>&#948;</italic><sub><italic>f</italic></sub></td><td>6/12 = 0.5</td></tr><tr><td>Rate of diagnostic evaluation for TB, per year</td><td/><td/></tr><tr><td>&#8195;Late active TB</td><td>Input into decision tree</td><td>5.0</td></tr><tr><td>&#8195;No active TB</td><td><italic>&#964;</italic><sub>0</sub></td><td>0.01</td></tr><tr><td>Decision tree outputs (in addition to unit costs):</td><td/><td>Vary by intervention</td></tr><tr><td>&#8195;Successful diagnosis rate of late active TB, per year</td><td><italic>&#963;</italic><sub><italic>hdip</italic></sub></td><td/></tr><tr><td>&#8195;Rate of movement from successful diagnosis to  treatment (1/diagnostic delay), per year</td><td><italic>&#961;</italic><sub><italic>hdip</italic></sub></td><td/></tr><tr><td>&#8195;Ineffective diagnosis rate of late active TB, per year</td><td><italic>&#954;</italic><sub><italic>hdip</italic></sub></td><td/></tr><tr><td>&#8195;Rate of diagnosis and treatment leading to new  resistance, per year</td><td/><td/></tr><tr><td>&#8195;susceptible to INH-monoresistant</td><td><italic>&#945;si</italic><sub><italic>hip</italic></sub></td><td/></tr><tr><td>&#8195;susceptible to MDR</td><td><italic>&#945;sm</italic><sub><italic>hip</italic></sub></td><td/></tr><tr><td>&#8195;INH-monoresistant to MDR</td><td><italic>&#945;im</italic><sub><italic>hip</italic></sub></td><td/></tr></tbody></table><table-wrap-foot><fn id="tblfn3"><label>*</label><p>Calculated such that (1&#8722;<italic>&#966;</italic><sub>1</sub>) = 0.25*(1&#8722;<italic>&#966;</italic><sub>2</sub>).</p></fn></table-wrap-foot></table-wrap>